Navigation Links
Federal Trade Commission Reports: Authorized Generics, During the 180-day Exclusivity Period, Benefit Consumers and the American Healthcare System
Date:6/25/2009

- Authorized Generics Benefit Consumers and Save the American Healthcare System Money

CINCINNATI, June 25 /PRNewswire/ -- Prasco Laboratories, a Mason-based independent authorized generic company, applauds the Federal Trade Commission (FTC) for issuing their interim report on the short and long-term effects of authorized generics on competition in the prescription drug marketplace.

Prasco commends the FTC in its approach. "This Interim Report is the result of a long and arduous process in response to a 2005 request by Senators Leahy, Grassley, and Rockefeller to review the impact of the practice of authorized generics on competition during the 180-day exclusivity period," stated E. Thomas Arington, Chairman and CEO of Prasco. "The Commission's analysis supports the pro-consumer impact of the increased competition that authorized generics bring to the generic drug industry, and the resulting savings to the American consumer," stated Arington.

According to the Interim Report, the FTC found that:

  • "...[C]onsumers benefit and the healthcare system saves money during the 180-day exclusivity period when an AG enters the market..." FTC report Authorized Generics: An Interim Report - June 2009; pg. 2

  • "...[C]onsumer harm arises from the absence of AG competition against an ANDA generic, not from the presence of AG competition against an ANDA generic." FTC report Authorized Generics: An Interim Report - June 2009; pg. 4

  • "I concur in the bottom-line conclusion of the Commission's Interim Report that the Report cannot properly be read to support a legislative ban on the marketing of Authorized Generics (AGs) during the 180-day exclusivity period (or otherwise) or to suggest that AGs are harmful to consumers." Concurring statement of FTC Commissioner J. Thomas Rosch

"In 1984, Congress enacted The Drug Price Competition and Patent Term Restoration Act, commonly known as Hatch-Waxman, to encourage the development of the generics industry in order to help consumers receive lower prices on prescription drugs. The practice of authorized generics embodies the spirit in which Hatch-Waxman was created: to bring Americans, high quality low-priced pharmaceuticals. We are pleased with the FTC's conclusion, in support of making pharmaceuticals more cost-effective for American consumers," Arington concluded.

About Prasco

Prasco is the authorized generics company, whose mission is to provide both quality products and significant cost-savings to the consumer. Prasco's goal is to provide patients with the Brand-Identical experience through Prasco Authorized Generics. To find out more about Prasco Authorized Generics, visit www.prasco.com or www.authorizedgenerics.com.

websites: www.prasco.com; www.authorizedgenerics.com


'/>"/>
SOURCE Prasco
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. MDMA Names New Director of Federal Affairs
2. Federal research plan to determine nanotech risks fails to deliver
3. Federal Employee Program Maintains Low Health Premiums In 2008
4. AMERIGROUP Contracts with Federal Government to Offer Medicare Advantage Health Plans in Seven States
5. SNM applauds NAS study showing need to restore federal nuclear medicine research funding
6. ACM Helps Medicaid Programs Comply With Federal Deficit Reduction Act Mandates
7. Boise(R) BEWARE(TM) Meets New Federal Guidelines Set Forth by Medicaid
8. HIV/AIDS Cases Among State and Federal Prison Inmates Fell for the Sixth Straight Year During 2005
9. Bristol-Myers Squibb Finalizes Settlement of Previously Disclosed Federal Investigation into Pricing, Sales and Marketing Practices
10. Federal Trade Commission Attempts To Suppress Best-Selling Authors First Amendment Rights
11. CPF Urges Congress to Increase Funding for IPF Research in 2009 Federal Budget
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... ... According to a new study by NCPA Senior Fellow John R. Graham, ... Congress has directed the CBO to follow. The CBO itself previously recognized Obamacare would ... estimates a reduction in employer-based coverage due to the GOP reform, which is not ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... $100,000 for its innovative EcoQube Frame vertical micro-veggies garden on Kickstarter . ... for the product – with nearly 2,000 consumers (and counting) already backing the ...
(Date:3/24/2017)... ... March 24, 2017 , ... Viewers who like to ... critical historical facts, cultural practices, goods, services, and societal issues tend to appreciate and ... into the popular practice of utilizing running events for causes around the world. ...
(Date:3/24/2017)... , ... March 24, 2017 , ... “End Time GPS”: ... salient events will interrelate. “End Time GPS” is the creation of published author, ... expert while working on military munitions and space-vehicle projects. Now, at age ninety-one, he ...
(Date:3/23/2017)... ... March 23, 2017 , ... A recent report from the National ... preparation programs. The NCTQ report suggests, based on a review of GPA and SAT/ACT ... teacher quality in the U.S. It argues that this higher bar should be set ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... Calif. , March 24, 2017 /PRNewswire/ ... epigenetics company, and Hamilton Robotics, Inc., who ... announced an ongoing collaboration that teams Zymo ... and RNA and DNA extraction products with ... already created optimized methods for microbiomics and ...
(Date:3/24/2017)... 2017   The Accreditation Council for Medical ... in the pharmaceutical industry has appointed Dr. ... newly formed scientific advisory board. Dr. Chin will ... first ever medical affairs think tank within the ... the ACMA, please visit  www.medicalaffairsspecialist.org .  Connect ...
(Date:3/24/2017)... Research and Markets has announced the addition of ... to their offering. ... IPF pipeline is very strong with a total of 97 drug candidates. ... and Sanofi are involved in the development of the IPF therapeutics. The ... Phase III stage, 15 are in Phase II stage, 12 are in ...
Breaking Medicine Technology: